Dermavant appoint Todd Zavodnick as CEO
Roivant subsidiary Dermavant has appointed experienced pharma exec Todd Zavodnick as the company’s new CEO.
The Rutger’s University graduate will take on the lead role in the dermatology focused subsidiary as he fills in for former Chief Executive Jackie Fouse, who left Dermavent in September of this year.
Bringing to the role more than 20 years of industry experience, Zavodnick is joining Dermavent from Silicon Valley-based biotech Revance in which he served as Chief Commercial Officer and President of Aesthetics and Therapeutics for more than a year.
“It is an honor to join Dermavant at such an exciting time in the company’s growth. Medical dermatology is a therapeutic area in need of real innovation, and that is precisely what we intend to provide at Dermavant,” Zavodnick said.
Zadovnick, who gained his BSc in pharmacy at Rutgers University in 1995, later achieved an MBA from the University of Texas at Dallas in 2006.
He later joined Novartis subsidiary Alcon, during which period he took on roles of increasing seniority for nearly nine years, after finally becoming President, Alcon China and Mongolia in 2009.
“We are thrilled to have Todd join Dermavant as we prepare to initiate our Phase 3 program for tapinarof,” said Frank Torti, M.D., Vant Investment Chair for Roivant Pharma and Chairman of the Board for Dermavant. “Todd’s deep expertise in dermatology will help Dermavant deliver innovative therapies to health care providers and patients worldwide.”
Zavodnick has previously served in global leadership roles at ZELTIQ Aesthetics, prior to Allergan’s acquisition of the company and at Galderma Laboratories.